A Multi-center, Open-label, Phase Ⅱb Trial to Evaluate the Safety and Efficacy of STSP-0601 for Injection in Patients With Hemophilia With Inhibitor
Latest Information Update: 28 Jan 2025
At a glance
- Drugs STSP-0601 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; Therapeutic Use
- Sponsors Staidson Beijing BioPharmaceuticals
Most Recent Events
- 22 Jan 2025 Status changed from recruiting to completed.
- 01 Apr 2024 Status changed from not yet recruiting to recruiting.
- 05 Mar 2024 New trial record